Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney

Phase III Stopped Early

Executive Summary

Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.

You may also be interested in...



Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye

Data is the new gold and Timmo Rousku Andersen, Boehringer Ingelheim’s corporate senior vice-president, head of global regions, outlines in an interview the German group's efforts to shape go-to-market models driven by data and insights. He also touches on digital therapeutics and how the firm’s R&D engine is pursuing deeper insights into interconnected disorders.

Boehringer Pharma Chief Confident Of Continued Success For Jardiance

Carinne Brouillon, head of the German major’s human pharma business unit, tells Scrip that Jardiance’s leadership in interconnected cardio-metabolic-renal diseases has been demonstrated and the product is set to keep rising as new indications come onboard.

Jardiance Gets Heart Failure Nod, But How Long Will Its Reign Last?

The SGLT2 inhibitor has better efficacy and clearer labeling than Novartis’s Entresto in heart failure with preserved ejection fraction, but AstraZeneca’s Farxiga is expected to produce Phase III data by June.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel